BeOne Medicines Ltd. (HKG:6160)
160.60
-4.70 (-2.84%)
Jun 16, 2025, 10:55 AM HKT
BeOne Medicines Revenue
BeOne Medicines had revenue of 8.11B CNY in the quarter ending March 31, 2025, with 49.38% growth. This brings the company's revenue in the last twelve months to 30.30B, up 51.91% year-over-year. In the year 2024, BeOne Medicines had annual revenue of 27.81B with 59.51% growth.
Revenue (ttm)
30.30B CNY
Revenue Growth
+51.91%
P/S Ratio
8.30
Revenue / Employee
2.75M CNY
Employees
11,000
Market Cap
269.70B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 27.81B | 10.38B | 59.51% |
Dec 31, 2023 | 17.43B | 7.67B | 78.53% |
Dec 31, 2022 | 9.77B | 2.29B | 30.69% |
Dec 31, 2021 | 7.47B | 5.46B | 270.56% |
Dec 31, 2020 | 2.02B | -965.08M | -32.37% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Hansoh Pharmaceutical Group Company | 13.05B |
Innovent Biologics | 10.03B |
JD Health International | 61.89B |
WuXi Biologics | 19.87B |
CSPC Pharmaceutical Group | 28.99B |
Sino Biopharmaceutical | 30.72B |
Akeso | 2.26B |
Sichuan Kelun-Biotech Biopharmaceutical | 2.06B |
BeOne Medicines News
- 6 days ago - Glenmark Pharmaceuticals to launch Zanubrutinib (BRUKINSA) in India after DCGI approval - Business Upturn
- 10 days ago - Cancer Stock Vaults 40% As Clinical Trial Shows 'Promise'; Sales Reach $1 Billion, Earnings To Triple - Investor's Business Daily
- 19 days ago - BeiGene gets EU backing for neck and head cancer treatment - Seeking Alpha
- 4 weeks ago - Market Shrugs Off This Drugmaker's Turnaround - Benzinga
- 4 weeks ago - Earnings Preview: BeiGene - Benzinga
- 4 weeks ago - Undercovered Dozen: Richtech Robotics, Intesa Sanpaolo, BeiGene, Analog Devices + - Seeking Alpha
- 5 weeks ago - BeiGene, Ltd., Soon To Be BeOne Medicines: New Name And New Profit - Seeking Alpha
- 5 weeks ago - BeiGene targets $4.9B-$5.3B revenue for 2025 with strong BRUKINSA and pipeline growth - Seeking Alpha